Physician profile
Yiming Yang
NPI 1467472746
$4,228.47
in general payments reported to CMS, 2019-2025
14 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $854 · 2021: $355 · 2022: $142 · 2023: $260 · 2024: $127 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,188.70 | 2019-2021 | |
| Inari Medical, INC. | $915.60 | 2019 | |
| Abbott Laboratories | $739.64 | 2020-2025 | Aveir |
| Medtronic Vascular, INC. | $390.56 | 2020 | |
| Cardiovascular Systems INC. | $279.07 | 2019-2021 | |
| Medtronic, INC. | $207.52 | 2023-2025 | Symplicity G3, Sinuva |
| Integra Lifesciences Corporation | $147.48 | 2020 | |
| Esperion Therapeutics, INC. | $137.23 | 2023-2025 | Nexletol, Nexlizet |
| Amgen INC. | $125.00 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $43.57 | 2025 | Verquvo |
| Contego Medical, INC | $19.24 | 2021 | |
| Glaxosmithkline, LLC. | $17.89 | 2025 | Arexvy, Shingrix |
| Zimvie INC. | $16.97 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiming Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.